See more : Captain Pipes Limited (CAPPIPES.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Aerpio Pharmaceuticals, Inc. (ARPO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aerpio Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Brookfield Office Properties Inc. (BRKFF) Income Statement Analysis – Financial Results
- Postmedia Network Canada Corp. (PCDAF) Income Statement Analysis – Financial Results
- Meghmani Organics Limited (MOL.BO) Income Statement Analysis – Financial Results
- PT Dharma Samudera Fishing Industries Tbk (DSFI.JK) Income Statement Analysis – Financial Results
- Yangzhou Seashine New Materials Co.,Ltd. (300885.SZ) Income Statement Analysis – Financial Results
Aerpio Pharmaceuticals, Inc. (ARPO)
About Aerpio Pharmaceuticals, Inc.
Aerpio Pharmaceuticals Inc. is a biopharmaceutical company, which engages in the research and development of treatments for ocular diseases. The company is headquartered in Blue Ash, Ohio and currently employs 27 full-time employees. The firm is focused on developing treatments for ocular disease. Its lead product candidate is AKB-9778. Its other two pipeline programs include AKB-4924 and ARP-1536. AKB-9778 is a small molecule activator of the Tie-2 pathway, which is being developed for the treatment of diabetic retinopathy (DR). AKB-4924 is a selective stabilizer of hypoxia-inducible factor-1 alpha (HIF-1alpha), which is being developed for the treatment of inflammatory bowel disease (IBD). ARP-1536 is a humanized monoclonal antibody directed at the same target as AKB-9778. ARP-1536 binds the extracellular domain of vascular endothelial protein tyrosine phosphatase (VE-PTP) inhibiting its ability to interact with Tie-2. As of April 14, 2017, the Company had completed a Phase II trial of AKB-9778 in 144 patients with diabetic macular edema. As of April 14, 2017, the Company had completed Phase Ia clinical trial in healthy volunteers for AKB-4924.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|
| Revenue | 5.51M | 4.47M | 823.00K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 35.02M | 20.02M | 14.44M | 8.32M | 0.00 | 0.00 |
| Gross Profit | -29.51M | -15.54M | -13.62M | -8.32M | 0.00 | 0.00 |
| Gross Profit Ratio | -535.75% | -347.36% | -1,655.04% | 0.00% | 0.00% | 0.00% |
| Research & Development | 35.02M | 20.02M | 14.44M | 9.82M | 15.14M | 12.75M |
| General & Administrative | 7.44M | 8.28M | 7.97M | 8.16M | 2.52M | 2.71M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 1.50M | 1.40M | 1.37M |
| SG&A | 7.44M | 8.28M | 7.97M | 9.67M | 3.92M | 4.08M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 7.44M | 7.56M | 7.96M | 10.32M | 15.93M | 15.33M |
| Cost & Expenses | 42.45M | 27.57M | 22.40M | 18.64M | 15.93M | 15.33M |
| Interest Income | 29.00K | 59.00K | 600.00K | 835.00K | 768.00K | 202.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 892.00K | 1.17M | 1.11M | 1.35M | 1.35M | 1.53M |
| EBITDA | -36.05M | -22.65M | -20.47M | -16.64M | -9.54M | -13.92M |
| EBITDA Ratio | -654.58% | -506.33% | -2,487.61% | 0.00% | 0.00% | 0.00% |
| Operating Income | -36.95M | -23.82M | -21.59M | -17.99M | -10.89M | -15.46M |
| Operating Income Ratio | -670.77% | -532.45% | -2,622.96% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 29.00K | 667.00K | -594.00K | -1.49M | -5.81M | 330.00K |
| Income Before Tax | -36.92M | -23.16M | -22.18M | -19.48M | -16.70M | -15.13M |
| Income Before Tax Ratio | -670.24% | -517.55% | -2,695.14% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -36.92M | -23.16M | -22.18M | -19.48M | -16.70M | -15.13M |
| Net Income Ratio | -670.24% | -517.55% | -2,695.14% | 0.00% | 0.00% | 0.00% |
| EPS | -1.08 | -0.96 | -1.35 | -2.43 | -3.59 | -2.25 |
| EPS Diluted | -1.08 | -0.96 | -1.35 | -2.43 | -3.59 | -2.25 |
| Weighted Avg Shares Out | 34.29M | 24.10M | 16.42M | 7.64M | 4.65M | 6.74M |
| Weighted Avg Shares Out (Dil) | 34.29M | 24.10M | 16.42M | 8.01M | 4.65M | 6.74M |
Aerpio Pharmaceuticals to Announce Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on Tuesday, March 13, 2018
Source: https://incomestatements.info
Category: Stock Reports